Medical Hemostatic Agents in the Netherlands reach buyers mainly through hospital group purchasing, specialist surgical distributors and direct sales teams from manufacturers. Dutch hospitals concentrate purchasing through regional purchasing cooperatives, so suppliers usually need a local distributor or a framework agreement to get onto the shelf. ASCs tend to buy through the same distributors at smaller volumes.
The biggest opportunities in the Netherlands Medical Hemostatic Agents market lie in bio-derived and synthetic combination agents, where surgeons want faster clot formation with fewer units used per procedure. Aging population and complex surgeries drive demand, so suppliers that can show clinical and cost benefits in cardiovascular and general surgery stand to gain. Product innovation and capacity expansion give entrants room to differentiate.
The Netherlands accounts for 4.6% of the European Medical Hemostatic Agents market in 2026, when Europe is valued at USD 1.5 Billion. That places the country sixth of the seven countries covered in Europe by 2033 market size. Germany, the UK, France, Italy and Spain all sit ahead of it, so the Netherlands is a mid-sized market with limited scale.
Medical Hemostatic Agents sold in the Netherlands must carry CE marking under EU medical device rules, with Dutch authorities supervising post-market surveillance and traceability. High cost and complex regulations restrain growth because smaller suppliers struggle with the documentation and clinical evidence needed for approval. Companies should plan for notified body review timelines before setting launch dates.
Dutch hospitals choose Medical Hemostatic Agents suppliers on clinical evidence, price per procedure and reliable supply, with procurement teams weighing all three together. Surgeons favour products that fit existing workflows in cardiovascular and general surgery, while purchasing departments push for volume discounts and stock guarantees. A local distributor with trained reps and quick restocking often decides the final selection.
| Region | CAGR (2019-2033) |
|---|---|
| Asia Pacific (fastest growing) | 0.27% |
| North America | -0.11% |
| Europe | -0.18% |
| Middle East & Africa | -0.51% |
| Latin America | -0.64% |

| By Product Type | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Thrombin-Based | 20.92 | 22.30 | 23.76 | 25.33 | 27.00 | 28.77 | 30.67 | 32.69 | 34.84 | 37.13 | 39.57 | 42.18 | 44.95 | 47.91 | 51.06 |
| Fibrin Sealants | 10.46 | 11.15 | 11.88 | 12.66 | 13.50 | 14.39 | 15.33 | 16.34 | 17.42 | 18.57 | 19.79 | 21.09 | 22.48 | 23.96 | 25.53 |
| ORC | 6.97 | 7.43 | 7.92 | 8.44 | 9.00 | 9.59 | 10.22 | 10.90 | 11.61 | 12.38 | 13.19 | 14.06 | 14.98 | 15.97 | 17.02 |
| Combination Agents | 5.23 | 5.57 | 5.94 | 6.33 | 6.75 | 7.19 | 7.67 | 8.17 | 8.71 | 9.28 | 9.89 | 10.54 | 11.24 | 11.98 | 12.77 |
| Total | 43.58 | 46.45 | 49.51 | 52.77 | 56.24 | 59.94 | 63.89 | 68.10 | 72.58 | 77.36 | 82.45 | 87.87 | 93.65 | 99.81 | 106.38 |

| By Application | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular | 20.92 | 22.30 | 23.76 | 25.33 | 27.00 | 28.77 | 30.67 | 32.69 | 34.84 | 37.13 | 39.57 | 42.18 | 44.95 | 47.91 | 51.06 |
| General Surgery | 10.46 | 11.15 | 11.88 | 12.66 | 13.50 | 14.39 | 15.33 | 16.34 | 17.42 | 18.57 | 19.79 | 21.09 | 22.48 | 23.96 | 25.53 |
| Trauma | 6.97 | 7.43 | 7.92 | 8.44 | 9.00 | 9.59 | 10.22 | 10.90 | 11.61 | 12.38 | 13.19 | 14.06 | 14.98 | 15.97 | 17.02 |
| Neurosurgery | 5.23 | 5.57 | 5.94 | 6.33 | 6.75 | 7.19 | 7.67 | 8.17 | 8.71 | 9.28 | 9.89 | 10.54 | 11.24 | 11.98 | 12.77 |
| Total | 43.58 | 46.45 | 49.51 | 52.77 | 56.24 | 59.94 | 63.89 | 68.10 | 72.58 | 77.36 | 82.45 | 87.87 | 93.65 | 99.81 | 106.38 |

| By End-User | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals | 29.05 | 30.97 | 33.01 | 35.18 | 37.50 | 39.96 | 42.60 | 45.40 | 48.39 | 51.57 | 54.97 | 58.58 | 62.44 | 66.55 | 70.92 |
| ASCs | 14.52 | 15.48 | 16.50 | 17.59 | 18.75 | 19.98 | 21.29 | 22.70 | 24.19 | 25.78 | 27.48 | 29.29 | 31.21 | 33.27 | 35.46 |
| Total | 43.58 | 46.45 | 49.51 | 52.77 | 56.24 | 59.94 | 63.89 | 68.10 | 72.58 | 77.36 | 82.45 | 87.87 | 93.65 | 99.81 | 106.38 |

| Report Attributes | Report Details |
| Base Year | 2025 |
| Historic Data | 2019-2024 |
| Market Size in 2026 | USD 68.10 Million |
| Market Forecast in 2033 | USD 106.38 Million |
| Growth Rate | CAGR of 6.58% |
| Study Period | 2026-2033 |
| Key Companies Profiled | Ethicon (Johnson & Johnson), Baxter International Inc., C. R. Bard (Becton Dickinson), Pfizer Inc., Takeda Pharmaceutical Company Limited, Teleflex Incorporated, B. Braun Melsungen AG, Advanced Medical Solutions Group plc, Gelita Medical GmbH, Stryker Corporation, Integra LifeSciences, CryoLife Inc. |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |

Need it tailored? Customize your report by selecting standalone sections, regional analyses, or detailed country-level insights. Contact our experts for a tailored solution at exclusive pricing.
Customize Your Research